Skip to main content
. 2017 Oct 8;9(28):1133–1140. doi: 10.4254/wjh.v9.i28.1133

Table 1.

Profile of patients with acute-on-chronic liver failure n (%)

APASL only (n = 14) EASL only (n = 15) Both (n = 49) P value3 Total (n = 78)
AGE (mean) 53 (48-57) 66 (61-71) 57 (54-60) 0.003 58 (55-61)
Race
Chinese 9 (64.3) 9 (60) 36 (73.5) 0.171 54 (69.2)
Malay 1 (7.1) 2 (13.3) 5 (10.2) 8 (10.3)
Indian 0 3 (20) 5 (10.2) 8 (10.3)
Others 4 (28.6) 1 (6.7) 3 (6.1) 8 (10.3)
Male gender 12 (85.7) 11 (73.3) 36 (73.5) 0.625 59 (75.6)
Diabetes mellitus 7 (50) 5 (33.3) 16 (32.7) 0.478 28 (35.9)
Cause of acute liver injury4
Infection 4 (28.6) 14 (93.3) 28 (57.1) 0.002 46 (59)
Hepatitis B flare 9 (64.3) 0 14 (28.6) 0.001 23 (29.5)
Variceal bleeding 4 (28.6) 2 (13.3) 13 (26.5) 0.535 19 (24.4)
Unknown cause 2 (14.3) 1 (6.7) 8 (16.3) 0.642 11 (14.1)
Alcohol 1 (7.1) 0 5 (10.2) 0.429 6 (7.7)
TCM 1 (7.1) 0 5 (10.2) 0.429 6 (7.7)
TIPSS 0 0 1 (2) 0.741 1 (1.3)
Underlying chronic liver disease
Hepatitis B 11 (78.6) 1 (6.7) 22 (44.9) < 0.0001 34 (43.6)
Alcohol 2 (14.3) 3 (20) 11 (22.4) 0.799 16 (20.5)
Cryptogenic 0 3 (20) 6 (12.2) 0.234 9 (11.5)
Hepatitis C 0 2 (13.3) 3 (6.1) 0.339 5 (6.4)
NASH 0 2 (13.3) 2 (4.1) 0.23 4 (5.1)
Hepatitis B + alcohol 1 (7.1) 0 1 (2) 0.444 2 (2.6)
Others1 0 4 (26.7) 5 (10.2) 0.072 9 (11.5)
Liver cirrhosis 6 (42.9) 15 (100) 49 (100) < 0.0001 70 (89.7)
HCC (Milan’s criteria) 0 1 (6.7) 4 (8.2) 0.627 5 (6.4)
Other cancers2 0 1 (6.7) 4 (8.2) 5 (6.4)
No malignancy 14 (100) 13 (86.7) 41 (83.7) 68 (87.2)
Previous decompensation 4 (28.6) 10 (66.7) 20 (43.5) 0.11 34 (45.3)
1

Other chronic liver diseases include Wilson's disease, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Congenital fibrosis, Drug-induced chronic liver disease and autoimmune liver disease;

2

Other cancers: Colon cancer, renal cell carcinoma, bladder cancer and ovarian cancer;

3

P-value of comparison of patients falling under APASL, EASL and both criteria;

4

Patients may have more than one cause of acute liver injury. TCM: Traditional Chinese Medicine; TIPSS: Transjugular intrahepatic portosystemic shunt; NASH: Non-alcoholic steatohepatitis; HCC: Hepatocellular carcinoma; APASL: Asia-Pacific Association for the Study of the Liver; EASL: European Association for the Study of the Liver.